Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Etigilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Etigilimab: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
PHP0101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
PHP0101: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Resiquimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Resiquimod: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
LW-231 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
LW-231: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
TZ-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
TZ-101: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Abalone haemocyanin(Marine Biotechnology Australia) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Abalone haemocyanin(Marine Biotechnology Australia): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
VR-102 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
VR-102: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
GSK-2696277 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
GSK-2696277: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
RD-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
RD-01: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Dendranib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Dendranib: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Afabicin diolamine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
Afabicin diolamine: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position.
8 min read
CM-4612 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
18 September 2026
CM-4612: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.